The estimated Net Worth of Anthony E Iii Maida is at least $120 Thousand dollars as of 29 May 2019. Anthony Maida owns over 50,000 units of 9 Meters Biopharma stock worth over $5,058 and over the last 21 years Anthony sold NMTR stock worth over $114,574.
Anthony has made over 21 trades of the 9 Meters Biopharma stock since 2011, according to the Form 4 filled with the SEC. Most recently Anthony exercised 50,000 units of NMTR stock worth $304,500 on 29 May 2019.
The largest trade Anthony's ever made was exercising 50,000 units of 9 Meters Biopharma stock on 29 May 2019 worth over $304,500. On average, Anthony trades about 3,832 units every 51 days since 2003. As of 29 May 2019 Anthony still owns at least 72,250 units of 9 Meters Biopharma stock.
You can see the complete history of Anthony Maida stock trades at the bottom of the page.
Anthony's mailing address filed with the SEC is C/O INNOVATE BIOPHARMACEUTICALS, INC.,, 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH, NC, 27615.
Over the last 5 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo, and John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
9 Meters Biopharma executives and other stock owners filed with the SEC include: